SCHEMBL15515432

SCHEMBL15515432

[c]1ccccc1OCC1CCNCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.51
SLC6A4 P31645 4/20 0.51
HTR3A P46098 2/20 0.51
KCNH2 Q12809 2/20 0.51
TDP1 Q9NUW8 1/20 0.46
KDM1A O60341 1/20 0.45
EP300 Q09472 1/20 0.43
SLC6A3 Q01959 3/20 0.42
GBA1 P04062 1/20 0.42
KHK P50053 1/20 0.42
IKBKB O14920 1/20 0.41
CHUK O15111 1/20 0.41
HTR4 Q13639 1/20 0.40
SYK P43405 1/20 0.40
MELK Q14680 1/20 0.39
GABRA1 P14867 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15515808 0.91 SLC6A2 (0.54) SLC6A2SLC6A4HTR3AKCNH2TDP1
SCHEMBL1221903 0.88 RIPK1 (0.44) SLC6A2SLC6A4HTR3AKCNH2SLC6A3
SCHEMBL4780152 0.85 HTR2C (0.42) SLC6A2SLC6A4HTR3AKCNH2
SCHEMBL4726241 0.85 MCHR1 (0.40)
SCHEMBL1986158 0.83 MCHR1 (0.41)
SCHEMBL12097795 0.77 NTRK1 (0.34) TDP1
SCHEMBL12483123 0.75 ALDH1A1 (0.31)
SCHEMBL12482533 0.75 MCHR1 (0.46)
SCHEMBL1895832 0.75 HRH1 (0.55) SLC6A2SLC6A4HTR3ASLC6A3HTR4
SCHEMBL796789 0.74 SLC6A2 (0.68) SLC6A2SLC6A4HTR3AKCNH2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2892892-A1 IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER Janssen Pharmaceutica N.V. (BE) 2015-07-15 EP disclosed
WO-2014039769-A1 IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER JANSSEN PHARMACEUTICA NV (BE) 2014-03-13 WO disclosed